Compulsions in OCD provide momentary relief but immediately strengthen the obsession they were meant to quiet. This paradox — acting to feel better only digs the hole deeper — is the defining mechanism that makes OCD so persistently debilitating.
OCD is ranked the 7th most debilitating illness on Earth — above many cancers — and the leading treatment, exposure-based CBT, works better than SSRIs alone, with no extra benefit from combining them.
Huberman Lab
OCD is ranked the 7th most debilitating illness on Earth — above many cancers — and the leading treatment, exposure-based CBT, works better than SSRIs alone, with no extra benefit from combining them.
TL;DR
Andrew Huberman breaks down the neuroscience and treatment landscape of OCD, a condition affecting up to 4% of people and ranked the 7th most debilitating illness worldwide [1] — Andrew Huberman "OCD prevalence: 2.5–4% of population: OCD affects an estimated 2.5% to as high as 4% of people, making it an astonishingly common condition." 01:00 . The cortico-striatal-thalamic loop drives the compulsion cycle, where engaging in a compulsion briefly relieves but ultimately strengthens the underlying obsession [2] — Andrew Huberman "OCD affects up to 4% of the population and is officially ranked the 7th most debilitating illness globally — outranking many physical disea…" 01:00 . Exposure-based CBT — not SSRIs — is the gold standard, cutting symptom severity scores nearly in half within four weeks [3] — Andrew Huberman "15 exposure sessions, twice weekly, over 12+ weeks: The standard exposure-based CBT protocol for OCD involves 2 planning sessions plus 15 e…" 24:10 . The single most useful takeaway: combining CBT with SSRIs offers no additional benefit over CBT alone.
Andrew Huberman explains the biology, psychology, and neural circuitry of OCD, detailing why compulsions reinforce obsessions, and reviews the most effective treatments including exposure-based CBT, SSRIs, TMS, mindfulness, and nutraceuticals.
Andrew Huberman sets the stage by introducing OCD as a disorder defined by intrusive, unwanted thoughts (obsessions) linked to repetitive behaviors (compulsions). The critical — and often misunderstood — dynamic is that compulsions don't solve obsessions; they briefly quiet them before amplifying their intensity. This self-reinforcing loop, Huberman emphasizes, is the defining tragedy of OCD. He then delivers two statistics that reframe the disorder's seriousness: up to 4% of the global population meets criteria for true OCD, and the condition sits at number 7 on the global list of most debilitating illnesses — not just mental health conditions, but all illnesses, outranking asthma and most cancers. The quality-of-life toll is immense, consuming hours or years of a person's capacity to work, relate to others, and engage in the activities that constitute a rich life.
Andrew Huberman sets the stage by introducing OCD as a disorder defined by intrusive, unwanted thoughts (obsessions) linked to repetitive behaviors (compulsions). The critical — and often misunderstood — dynamic is that compulsions don't solve obsessions; they briefly quiet them before amplifying their intensity. This self-reinforcing loop, Huberman emphasizes, is the defining tragedy of OCD. He then delivers two statistics that reframe the disorder's seriousness: up to 4% of the global population meets criteria for true OCD, and the condition sits at number 7 on the global list of most debilitating illnesses — not just mental health conditions, but all illnesses, outranking asthma and most cancers. The quality-of-life toll is immense, consuming hours or years of a person's capacity to work, relate to others, and engage in the activities that constitute a rich life.
Huberman systematically breaks down OCD into its three core behavioral categories: checking (e.g., stove, locks), repetition (e.g., counting sequences), and order. Order turns out to be the most expansive and counterintuitive category — it covers not just cleanliness but also incompleteness (the feeling that one cannot stop until something feels 'right'), symmetry, and contamination/disgust. The contamination subtype, commonly associated with excessive handwashing, emerges logically from this framework as a response to the perceived uncleanliness of spaces, objects, or other people. Huberman illustrates these abstract categories with relatable examples — children arranging stuffed animals in exact positions and experiencing genuine distress when the arrangement is disturbed. Throughout, he returns to his central thesis: each compulsive act, no matter which category it falls in, reinforces the obsession rather than resolving it.
Huberman systematically breaks down OCD into its three core behavioral categories: checking (e.g., stove, locks), repetition (e.g., counting sequences), and order. Order turns out to be the most expansive and counterintuitive category — it covers not just cleanliness but also incompleteness (the feeling that one cannot stop until something feels 'right'), symmetry, and contamination/disgust. The contamination subtype, commonly associated with excessive handwashing, emerges logically from this framework as a response to the perceived uncleanliness of spaces, objects, or other people. Huberman illustrates these abstract categories with relatable examples — children arranging stuffed animals in exact positions and experiencing genuine distress when the arrangement is disturbed. Throughout, he returns to his central thesis: each compulsive act, no matter which category it falls in, reinforces the obsession rather than resolving it.
Before diving into genetics and neuroscience, Huberman pauses to define the emotional landscape of OCD. Fear, he explains, involves heightened autonomic arousal — racing heart, rapid breathing, sweating — in direct response to a present and identifiable threat. Anxiety shares the same physiological profile but crucially lacks a clear, present danger. In OCD, anxiety is the invisible line that connects an intrusive thought (obsession) to a driven behavior (compulsion). A person obsessed with germs is not reacting to a measurable threat in front of them; they're experiencing anxiety about a perceived and anticipated threat. This distinction matters clinically: treatment strategies need to address the anxiety response itself, not just the surface behaviors, and this sets up everything that follows about CBT and pharmacology.
Huberman explores the hereditary dimension of OCD through the lens of twin studies — comparing identical twins (including monocorionic pairs sharing the same gestational sac), fraternal twins, and non-twin populations. The broad conclusion: approximately 40 to 50% of OCD cases have some identifiable genetic component. Huberman acknowledges this is interesting but tempers expectations about its clinical utility — people can't choose their genes or their parents. What this data does usefully establish is that OCD is not purely a product of upbringing or environment; biology loads the gun for about half of sufferers. For the other half, the disorder appears to arise through other pathways, underscoring the importance of neurological and behavioral mechanisms as intervention targets.
With genetic context established, Huberman shifts to the neural architecture of OCD. He identifies three key structures: the cortex, responsible for conscious perception and understanding; the striatum and basal ganglia, which generate and suppress actions through a go/no-go mechanism; and the thalamus, an egg-shaped relay center in the brain's core that channels sensory information — sight, sound, touch — upward toward conscious experience. Wrapping the thalamus is the thalamic reticular nucleus, a structure Huberman calls one of his favorites in neuroanatomy. This outer shell acts as a filter, deciding which streams of sensory experience are passed up to conscious awareness and which are blocked. The stage is now set to show how these three structures talk to each other — and how their conversation goes wrong in OCD.
This is the episode's richest neuroscience chapter. Huberman describes how researchers have confirmed the cortico-striatal-thalamic loop's role in OCD through deliberately provocative experiments: subjects with contamination OCD are handed towels soaked in a stranger's sweat — sometimes from the back of the experimenter's neck — and placed in brain scanners. The anxiety, obsessions, and compulsive urges that flood in correspond exactly to heightened metabolic activity in this circuit. The evidence becomes even more compelling when drug data is layered on: SSRIs that partially relieve OCD symptoms don't just change behavior, they measurably reduce activity in the same cortico-striatal-thalamic circuit. The convergence of fMRI data, PET scanning, and pharmacological effects from multiple independent research groups creates one of the stronger causal arguments in psychiatric neuroscience. Huberman also teases how understanding this circuit illuminates why each treatment approach — behavioral, pharmacological, or stimulation-based — targets different nodes of the same loop.
The second sponsor segment features Eight Sleep, whose Pod 5 smart mattress cover Huberman describes as a sleep quality game-changer he has used for nearly five years. He grounds the pitch in physiology: falling and staying asleep requires body temperature to drop 1–3 degrees, while waking refreshed requires it to rise by the same amount. The Pod 5's Autopilot feature — an AI engine that learns a user's individual sleep patterns and adjusts temperature accordingly across sleep stages — automates this process. The product can also elevate the head if the user is snoring. Eight Sleep ships internationally, including to Mexico and the UAE, and the promotional offer is up to $350 off at eightsleep.com/huberman.
With the neuroscience grounded, Huberman turns to clinical diagnosis. The Yale-Brown Obsessive Compulsive Scale — colloquially the Y-BOCS — is the field's most widely used and comprehensive diagnostic instrument, running dozens of pages. Huberman reads directly from the instrument's patient-facing definitions: obsessions are unwelcome, distressing, intrusive thoughts that may feel repugnant or senseless; compulsions are behaviors the patient feels driven to perform despite often recognizing them as excessive. The Y-BOCS surveys an enormous range of obsession types — aggressive (fear of harming oneself or others), contamination, sexual, saving, and moral (concern with right/wrong, sacrilege, blasphemy) — along with their compulsive counterparts. Huberman notes that the scale covers both current and past symptom presence, and hints at why identifying the precise fear underlying symptoms, not just the surface behaviors, is what makes treatment possible.
Beyond its survey of symptoms, the Y-BOCS serves a more strategic clinical purpose: forcing patients and clinicians alike to move past surface-level obsessions and compulsions toward the terror beneath. What would actually happen if the compulsion were not performed? What is the worst-case scenario the obsession is guarding against? Huberman argues that naming this core catastrophic fear precisely — not generically — is essential for treatment to work. It's the difference between knowing a patient washes their hands and understanding that they believe not washing will cause a loved one to die. This depth of specification, he reveals, determines how well exposure-based therapy can be targeted and executed. The clearer the fear, the more precisely the circuit can be interrupted.
Huberman introduces the treatment that the episode's data will ultimately crown as the most effective for OCD: exposure and response prevention, delivered within a CBT framework. The approach is deliberately and necessarily uncomfortable. Unlike other anxiety interventions that aim to reduce or regulate distress through breathing or visualization, OCD-focused CBT amplifies it — patients are guided step by step toward their exact fear, then prevented from performing their normal compulsion. The logic maps directly onto the neural circuit: the striatum's go/no-go system is being retrained to decouple the anxiety signal from the compulsive action. Each time the anxiety is felt without the compulsion following, the circuit weakens slightly. Huberman is unambiguous that this is clinical work — not a self-help exercise — and must be conducted by trained, licensed psychologists and psychiatrists who can safely hold a patient in an extremely activated state.
Huberman elaborates on the mechanics of exposure therapy, stressing that the process is progressive and hierarchical rather than abrupt. Patients are not immediately confronted with their worst fear; they are gently moved through a ladder of increasingly distressing scenarios, building tolerance at each rung. The clinical goal is not desensitization in the traditional sense — it's not that the patient stops feeling anxiety. Rather, the patient learns through repeated experience that the anxiety can be felt fully and then dissipate without a compulsion ever occurring. This is a radical reframing for people with OCD, who have often lived for years with the belief that anxiety is intolerable unless immediately relieved through action. The realization — experientially, not just intellectually — that anxiety can be survived without compulsion is the mechanism of change.
Huberman centers the treatment discussion around one of the field's most prominent figures: Dr. Helen Blair Simpson, MD/PhD, of Columbia University School of Medicine. He positions her as arguably the preeminent active OCD researcher-clinician in the world. Her protocol is specific and structured: two initial planning sessions orient the patient to exactly what will happen — what they'll face, when, and how long. Then 15 exposure sessions are conducted twice a week, each pushing the patient progressively closer to their core fear and preventing the compulsive response (ritual prevention). The total course typically runs 10 to 12 weeks. The planning sessions are not trivial; they are what allow patients to consent meaningfully and approach the exposures with enough trust and context to tolerate the intensity. Without that framing, the approach could feel traumatic rather than therapeutic.
The episode's most clinically significant moment arrives in this chapter. Huberman presents the findings of Dr. Blair Simpson's landmark comparison study pitting exposure-based CBT against SSRIs and placebo. Placebo produced no meaningful reduction in OCD symptoms. SSRIs produced a significant but modest improvement. CBT, however, was transformative: Y-BOCS scores dropped from approximately 25 all the way down to about 11 within just four weeks — a nearly 60% reduction in symptom severity. When SSRIs and CBT were combined, the results were almost identical to CBT alone. There was no synergistic benefit from the combination. This finding has direct clinical implications: for patients already on SSRIs, adding CBT is the priority; for patients considering treatment, CBT alone may be sufficient and may be the more powerful starting point.
The third sponsor segment features Rorra Water Filters, which Huberman positions as his preferred solution to tap water contamination. He grounds the pitch in a 2020 Environmental Working Group study estimating that over 200 million Americans are exposed to PFAS 'forever chemicals' through tap water — chemicals linked to hormone disruption, gut microbiome damage, and fertility issues. Rorra's countertop system removes these and other harmful compounds while preserving beneficial minerals like magnesium and calcium. Huberman highlights the product's no-installation convenience, medical-grade stainless steel construction, and countertop aesthetic. The offer is an exclusive discount at rorra.com/huberman.
Having established CBT's superiority, Huberman pivots to a philosophically important point about SSRIs and psychiatric medicine more broadly. SSRIs do help some OCD patients — reducing symptoms measurably compared to placebo — but the scientific literature provides almost no evidence that OCD is caused by or rooted in serotonin system dysfunction. This is not a minor footnote; it's a fundamental challenge to how psychiatric pharmacology is often understood. Drugs are frequently assumed to reveal the biology of a disorder by the mechanism through which they help. Huberman argues this logic is flawed, and OCD is a clear example: the drug works (somewhat) but the implied causation is unjustified. He broadens this observation to depression, anxiety, and other psychiatric conditions — a recurring theme he believes clinicians and patients deserve to understand.
Huberman examines two treatments that generate significant public interest. First, cannabis: a human laboratory study by Dr. Blair Simpson found that smoked cannabis — whether THC-dominant or CBD — had little acute effect on OCD symptoms and, critically, produced smaller reductions in anxiety than placebo. This is a striking finding given widespread beliefs about cannabis as an anxiolytic. Second, transcranial magnetic stimulation: TMS coils applied non-invasively to motor and supplementary motor areas of the skull can interrupt the automatic quality of compulsive motor behaviors. Small-scale studies have shown reductions in OCD symptoms that persist after treatment ends. Huberman tempers enthusiasm by calling TMS promising rather than proven, and notes that the greatest excitement surrounds combinations of TMS with CBT or pharmacological treatment.
Huberman surveys the holistic treatment landscape, starting with mindfulness meditation. A study from Dr. Blair Simpson's own lab suggests meditation's benefits for OCD are real but indirect — improvements appear to come from increased focus and adherence to CBT homework rather than from any direct neurological effect on the OCD circuit. Huberman frames this as still meaningful: anything that improves CBT engagement ultimately improves outcomes. He then zooms out to a broader institutional development: the NIH has launched an entire dedicated division — the Division of Complementary Health — to formally study practices like meditation, yoga nidra, and breathing techniques. This signals a cultural and scientific shift in which holistic approaches are no longer fringe but subjects of rigorous inquiry, standing alongside the Cancer Institute and Vision Institute as federally funded research priorities.
The episode closes with a look at nutraceuticals, focusing on myo-inositol — a naturally occurring sugar alcohol available over the counter. At 900 milligrams or higher, it appears to improve sleep and may reduce anxiety, and Huberman sees genuine potential for it as a complementary tool in OCD treatment, provided it is studied more systematically in combination with behavioral therapies and possibly TMS. He is careful not to oversell it, noting that the research is still early. In his closing remarks, Huberman returns to the episode's central argument: understanding the cortico-striatal-thalamic loop — why it misfires in OCD and how each treatment targets a different node — equips patients and their clinicians to make far better treatment decisions. He closes with empathy for those living with OCD, urging listeners who recognize themselves or someone they know to pursue informed, expert-guided care.
Chapter 1 · 00:00
Andrew Huberman sets the stage by introducing OCD as a disorder defined by intrusive, unwanted thoughts (obsessions) linked to repetitive behaviors (compulsions). The critical — and often misunderstood — dynamic is that compulsions don't solve obsessions; they briefly quiet them before amplifying their intensity. This self-reinforcing loop, Huberman emphasizes, is the defining tragedy of OCD. He then delivers two statistics that reframe the disorder's seriousness: up to 4% of the global population meets criteria for true OCD, and the condition sits at number 7 on the global list of most debilitating illnesses — not just mental health conditions, but all illnesses, outranking asthma and most cancers. The quality-of-life toll is immense, consuming hours or years of a person's capacity to work, relate to others, and engage in the activities that constitute a rich life.
Compulsions in OCD provide momentary relief but immediately strengthen the obsession they were meant to quiet. This paradox — acting to feel better only digs the hole deeper — is the defining mechanism that makes OCD so persistently debilitating.
Chapter 2 · 00:11
Andrew Huberman sets the stage by introducing OCD as a disorder defined by intrusive, unwanted thoughts (obsessions) linked to repetitive behaviors (compulsions). The critical — and often misunderstood — dynamic is that compulsions don't solve obsessions; they briefly quiet them before amplifying their intensity. This self-reinforcing loop, Huberman emphasizes, is the defining tragedy of OCD. He then delivers two statistics that reframe the disorder's seriousness: up to 4% of the global population meets criteria for true OCD, and the condition sits at number 7 on the global list of most debilitating illnesses — not just mental health conditions, but all illnesses, outranking asthma and most cancers. The quality-of-life toll is immense, consuming hours or years of a person's capacity to work, relate to others, and engage in the activities that constitute a rich life.
Claims made here
OCD affects 2.5% to 4% of the global population.
OCD is ranked number 7 among all illnesses worldwide in terms of debilitation, surpassing diseases like asthma and many cancers.
Every time a person engages in a compulsion related to their obsession, the obsession grows stronger rather than being relieved — the defining paradox of OCD.
OCD affects up to 4% of the population and is officially ranked the 7th most debilitating illness globally — outranking many physical diseases. It consumes so much mental bandwidth that everyday functioning, relationships, and work all suffer profoundly.
OCD affects an estimated 2.5% to as high as 4% of people, making it an astonishingly common condition.
OCD is currently ranked number 7 among all illnesses — not just mental disorders — in terms of overall debilitation, outranking conditions like asthma and many cancers.
OCD organizes into three core bins: checking, repetition, and order. Order is broader than tidiness — it includes incompleteness, symmetry, and contamination/disgust, explaining why handwashing fits alongside needing stuffed animals in a precise arrangement.
Chapter 3 · 01:54
Huberman systematically breaks down OCD into its three core behavioral categories: checking (e.g., stove, locks), repetition (e.g., counting sequences), and order. Order turns out to be the most expansive and counterintuitive category — it covers not just cleanliness but also incompleteness (the feeling that one cannot stop until something feels 'right'), symmetry, and contamination/disgust. The contamination subtype, commonly associated with excessive handwashing, emerges logically from this framework as a response to the perceived uncleanliness of spaces, objects, or other people. Huberman illustrates these abstract categories with relatable examples — children arranging stuffed animals in exact positions and experiencing genuine distress when the arrangement is disturbed. Throughout, he returns to his central thesis: each compulsive act, no matter which category it falls in, reinforces the obsession rather than resolving it.
Chapter 5 · 05:20
Before diving into genetics and neuroscience, Huberman pauses to define the emotional landscape of OCD. Fear, he explains, involves heightened autonomic arousal — racing heart, rapid breathing, sweating — in direct response to a present and identifiable threat. Anxiety shares the same physiological profile but crucially lacks a clear, present danger. In OCD, anxiety is the invisible line that connects an intrusive thought (obsession) to a driven behavior (compulsion). A person obsessed with germs is not reacting to a measurable threat in front of them; they're experiencing anxiety about a perceived and anticipated threat. This distinction matters clinically: treatment strategies need to address the anxiety response itself, not just the surface behaviors, and this sets up everything that follows about CBT and pharmacology.
Anxiety is the connective tissue binding obsessions to compulsions in OCD. It's not the same as fear — anxiety lacks a clear and present danger — but it produces the same physiological storm that drives people to act out their compulsions for temporary relief.
Chapter 6 · 06:40
Huberman explores the hereditary dimension of OCD through the lens of twin studies — comparing identical twins (including monocorionic pairs sharing the same gestational sac), fraternal twins, and non-twin populations. The broad conclusion: approximately 40 to 50% of OCD cases have some identifiable genetic component. Huberman acknowledges this is interesting but tempers expectations about its clinical utility — people can't choose their genes or their parents. What this data does usefully establish is that OCD is not purely a product of upbringing or environment; biology loads the gun for about half of sufferers. For the other half, the disorder appears to arise through other pathways, underscoring the importance of neurological and behavioral mechanisms as intervention targets.
Claims made here
Approximately 40–50% of OCD cases have an identifiable genetic component, based on twin studies.
Dozens to hundreds of neuroimaging studies have identified the cortico-striatal-thalamic loop as the primary brain circuit generating OCD obsessions and compulsions.
About 40 to 50% of OCD cases have a genetic component, as revealed by twin studies examining identical and fraternal twins. But genes aren't destiny — a substantial portion of OCD arises without any identifiable inherited factor.
Twin studies suggest that roughly 40 to 50% of OCD cases have an identifiable genetic component, though genes cannot be controlled.
Dozens to hundreds of neuroimaging studies converge on one circuit: the cortico-striatal-thalamic loop. The cortex processes perception, the striatum governs go/no-go action, and the thalamus gates what reaches consciousness. When this loop misfires, intrusive thoughts and compulsive behaviors emerge.
Dozens to hundreds of neuroimaging studies point to the cortico-striatal-thalamic loop as the primary neural circuit generating obsessions and compulsions in OCD.
Chapter 7 · 08:45
With genetic context established, Huberman shifts to the neural architecture of OCD. He identifies three key structures: the cortex, responsible for conscious perception and understanding; the striatum and basal ganglia, which generate and suppress actions through a go/no-go mechanism; and the thalamus, an egg-shaped relay center in the brain's core that channels sensory information — sight, sound, touch — upward toward conscious experience. Wrapping the thalamus is the thalamic reticular nucleus, a structure Huberman calls one of his favorites in neuroanatomy. This outer shell acts as a filter, deciding which streams of sensory experience are passed up to conscious awareness and which are blocked. The stage is now set to show how these three structures talk to each other — and how their conversation goes wrong in OCD.
Chapter 8 · 10:16
This is the episode's richest neuroscience chapter. Huberman describes how researchers have confirmed the cortico-striatal-thalamic loop's role in OCD through deliberately provocative experiments: subjects with contamination OCD are handed towels soaked in a stranger's sweat — sometimes from the back of the experimenter's neck — and placed in brain scanners. The anxiety, obsessions, and compulsive urges that flood in correspond exactly to heightened metabolic activity in this circuit. The evidence becomes even more compelling when drug data is layered on: SSRIs that partially relieve OCD symptoms don't just change behavior, they measurably reduce activity in the same cortico-striatal-thalamic circuit. The convergence of fMRI data, PET scanning, and pharmacological effects from multiple independent research groups creates one of the stronger causal arguments in psychiatric neuroscience. Huberman also teases how understanding this circuit illuminates why each treatment approach — behavioral, pharmacological, or stimulation-based — targets different nodes of the same loop.
Claims made here
SSRIs suppress activity in the cortico-striatal-thalamic loop, corresponding to their reduction of OCD symptoms.
Researchers handed OCD patients a towel soaked in a stranger's sweat, then scanned their brains. The cortico-striatal-thalamic loop lit up every time. SSRIs that reduced symptoms also quieted these exact regions, creating convergent proof that this circuit drives OCD.
Chapter 10 · 16:00
With the neuroscience grounded, Huberman turns to clinical diagnosis. The Yale-Brown Obsessive Compulsive Scale — colloquially the Y-BOCS — is the field's most widely used and comprehensive diagnostic instrument, running dozens of pages. Huberman reads directly from the instrument's patient-facing definitions: obsessions are unwelcome, distressing, intrusive thoughts that may feel repugnant or senseless; compulsions are behaviors the patient feels driven to perform despite often recognizing them as excessive. The Y-BOCS surveys an enormous range of obsession types — aggressive (fear of harming oneself or others), contamination, sexual, saving, and moral (concern with right/wrong, sacrilege, blasphemy) — along with their compulsive counterparts. Huberman notes that the scale covers both current and past symptom presence, and hints at why identifying the precise fear underlying symptoms, not just the surface behaviors, is what makes treatment possible.
The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) spans dozens of pages and dozens of categories from aggressive and contamination obsessions to sexual and moral ones. Its deeper purpose is not just mapping symptoms but unearthing the patient's most catastrophic underlying fear, which is the true target of treatment.
Chapter 11 · 18:00
Beyond its survey of symptoms, the Y-BOCS serves a more strategic clinical purpose: forcing patients and clinicians alike to move past surface-level obsessions and compulsions toward the terror beneath. What would actually happen if the compulsion were not performed? What is the worst-case scenario the obsession is guarding against? Huberman argues that naming this core catastrophic fear precisely — not generically — is essential for treatment to work. It's the difference between knowing a patient washes their hands and understanding that they believe not washing will cause a loved one to die. This depth of specification, he reveals, determines how well exposure-based therapy can be targeted and executed. The clearer the fear, the more precisely the circuit can be interrupted.
Chapter 12 · 19:30
Huberman introduces the treatment that the episode's data will ultimately crown as the most effective for OCD: exposure and response prevention, delivered within a CBT framework. The approach is deliberately and necessarily uncomfortable. Unlike other anxiety interventions that aim to reduce or regulate distress through breathing or visualization, OCD-focused CBT amplifies it — patients are guided step by step toward their exact fear, then prevented from performing their normal compulsion. The logic maps directly onto the neural circuit: the striatum's go/no-go system is being retrained to decouple the anxiety signal from the compulsive action. Each time the anxiety is felt without the compulsion following, the circuit weakens slightly. Huberman is unambiguous that this is clinical work — not a self-help exercise — and must be conducted by trained, licensed psychologists and psychiatrists who can safely hold a patient in an extremely activated state.
Effective OCD therapy is deliberately uncomfortable: patients are guided to feel maximal anxiety and then blocked from performing their compulsion. This directly retrains the cortico-striatal-thalamic loop by teaching the brain that the anxiety can exist without requiring action.
Chapter 13 · 21:39
Huberman elaborates on the mechanics of exposure therapy, stressing that the process is progressive and hierarchical rather than abrupt. Patients are not immediately confronted with their worst fear; they are gently moved through a ladder of increasingly distressing scenarios, building tolerance at each rung. The clinical goal is not desensitization in the traditional sense — it's not that the patient stops feeling anxiety. Rather, the patient learns through repeated experience that the anxiety can be felt fully and then dissipate without a compulsion ever occurring. This is a radical reframing for people with OCD, who have often lived for years with the belief that anxiety is intolerable unless immediately relieved through action. The realization — experientially, not just intellectually — that anxiety can be survived without compulsion is the mechanism of change.
Chapter 14 · 23:23
Huberman centers the treatment discussion around one of the field's most prominent figures: Dr. Helen Blair Simpson, MD/PhD, of Columbia University School of Medicine. He positions her as arguably the preeminent active OCD researcher-clinician in the world. Her protocol is specific and structured: two initial planning sessions orient the patient to exactly what will happen — what they'll face, when, and how long. Then 15 exposure sessions are conducted twice a week, each pushing the patient progressively closer to their core fear and preventing the compulsive response (ritual prevention). The total course typically runs 10 to 12 weeks. The planning sessions are not trivial; they are what allow patients to consent meaningfully and approach the exposures with enough trust and context to tolerate the intensity. Without that framing, the approach could feel traumatic rather than therapeutic.
Columbia's Dr. Helen Blair Simpson — one of the world's top OCD researchers and clinicians — uses a structured protocol: 2 orientation sessions followed by 15 exposure sessions twice weekly. Crucially, patients know exactly what to expect before they're confronted with their core fears.
The standard exposure-based CBT protocol for OCD involves 2 planning sessions plus 15 exposure sessions done twice a week, typically spanning 10 to 12 weeks or more.
Chapter 15 · 25:18
The episode's most clinically significant moment arrives in this chapter. Huberman presents the findings of Dr. Blair Simpson's landmark comparison study pitting exposure-based CBT against SSRIs and placebo. Placebo produced no meaningful reduction in OCD symptoms. SSRIs produced a significant but modest improvement. CBT, however, was transformative: Y-BOCS scores dropped from approximately 25 all the way down to about 11 within just four weeks — a nearly 60% reduction in symptom severity. When SSRIs and CBT were combined, the results were almost identical to CBT alone. There was no synergistic benefit from the combination. This finding has direct clinical implications: for patients already on SSRIs, adding CBT is the priority; for patients considering treatment, CBT alone may be sufficient and may be the more powerful starting point.
Claims made here
Exposure-based CBT reduced OCD symptom severity scores (on a scale of 8–28) from approximately 25 down to about 11 within four weeks.
When CBT, SSRIs, and placebo were compared head-to-head, CBT halved OCD symptom severity scores within four weeks. SSRIs helped — but left patients substantially more symptomatic than CBT alone. Combining them added nothing extra.
Exposure-based CBT reduced OCD symptom severity scores from approximately 25 down to about 11 within four weeks — a dramatic clinical improvement.
Chapter 17 · 27:05
Having established CBT's superiority, Huberman pivots to a philosophically important point about SSRIs and psychiatric medicine more broadly. SSRIs do help some OCD patients — reducing symptoms measurably compared to placebo — but the scientific literature provides almost no evidence that OCD is caused by or rooted in serotonin system dysfunction. This is not a minor footnote; it's a fundamental challenge to how psychiatric pharmacology is often understood. Drugs are frequently assumed to reveal the biology of a disorder by the mechanism through which they help. Huberman argues this logic is flawed, and OCD is a clear example: the drug works (somewhat) but the implied causation is unjustified. He broadens this observation to depression, anxiety, and other psychiatric conditions — a recurring theme he believes clinicians and patients deserve to understand.
Claims made here
Combining SSRIs with CBT for OCD produced no additional reduction in symptoms compared to CBT alone.
There is very little, if any, evidence that the serotonin system is causally disrupted in OCD, despite SSRIs being partially effective.
Combining SSRIs with cognitive behavioral therapy did not produce any further decrease in OCD symptoms compared to CBT alone, confirming CBT as the primary driver of improvement.
SSRIs reduce OCD symptoms in some patients, yet there is almost no evidence that the serotonin system is causally disrupted in OCD. This is a broader problem in psychiatry: drugs that work don't necessarily tell us what's broken.
Despite SSRIs being partially effective for OCD, there is very little evidence that the serotonin system itself is causally disrupted in OCD — a recurring theme in psychiatry.
Chapter 18 · 29:09
Huberman examines two treatments that generate significant public interest. First, cannabis: a human laboratory study by Dr. Blair Simpson found that smoked cannabis — whether THC-dominant or CBD — had little acute effect on OCD symptoms and, critically, produced smaller reductions in anxiety than placebo. This is a striking finding given widespread beliefs about cannabis as an anxiolytic. Second, transcranial magnetic stimulation: TMS coils applied non-invasively to motor and supplementary motor areas of the skull can interrupt the automatic quality of compulsive motor behaviors. Small-scale studies have shown reductions in OCD symptoms that persist after treatment ends. Huberman tempers enthusiasm by calling TMS promising rather than proven, and notes that the greatest excitement surrounds combinations of TMS with CBT or pharmacological treatment.
Claims made here
Smoked cannabis (THC or CBD) had little acute impact on OCD symptoms and produced smaller anxiety reductions than placebo.
TMS applied to motor and supplementary motor areas can reduce OCD compulsive behaviors even after the treatment session ends.
A rigorous human laboratory study by Dr. Helen Blair Simpson found that smoked cannabis — whether THC-dominant or CBD — had little acute effect on OCD symptoms and actually produced smaller anxiety reductions than placebo. The popular belief that cannabis helps OCD isn't supported by the data.
A human laboratory study found that smoked cannabis — whether THC-dominant or CBD — had little acute impact on OCD symptoms and produced smaller anxiety reductions than placebo.
Transcranial magnetic stimulation targeted at motor and supplementary motor areas can interrupt the automatic quality of compulsive behaviors, with symptom reductions persisting after the sessions end. TMS isn't a magic bullet, but its combination with CBT or drug treatment is generating real excitement.
Transcranial magnetic stimulation applied to motor and supplementary motor areas can interrupt compulsive motor behaviors and reduce OCD symptoms beyond the active treatment session.
Chapter 19 · 31:48
Huberman surveys the holistic treatment landscape, starting with mindfulness meditation. A study from Dr. Blair Simpson's own lab suggests meditation's benefits for OCD are real but indirect — improvements appear to come from increased focus and adherence to CBT homework rather than from any direct neurological effect on the OCD circuit. Huberman frames this as still meaningful: anything that improves CBT engagement ultimately improves outcomes. He then zooms out to a broader institutional development: the NIH has launched an entire dedicated division — the Division of Complementary Health — to formally study practices like meditation, yoga nidra, and breathing techniques. This signals a cultural and scientific shift in which holistic approaches are no longer fringe but subjects of rigorous inquiry, standing alongside the Cancer Institute and Vision Institute as federally funded research priorities.
Claims made here
Mindfulness meditation improves OCD symptoms indirectly by enhancing patients' engagement with CBT homework, rather than by directly relieving OCD symptoms.
Mindfulness meditation doesn't directly treat OCD but improves engagement with CBT homework. Myo-inositol at 900mg+ may reduce anxiety and improve sleep. The NIH's new Division of Complementary Health is now funding the systematic study of these approaches.
The National Institutes of Health now has an entire division dedicated to exploring complementary and holistic treatments like breathing practices and meditation for psychiatric disorders.
Mindfulness meditation appears to improve OCD outcomes not by directly reducing symptoms but by increasing a patient's focus and engagement with CBT homework.
Chapter 20 · 33:40
The episode closes with a look at nutraceuticals, focusing on myo-inositol — a naturally occurring sugar alcohol available over the counter. At 900 milligrams or higher, it appears to improve sleep and may reduce anxiety, and Huberman sees genuine potential for it as a complementary tool in OCD treatment, provided it is studied more systematically in combination with behavioral therapies and possibly TMS. He is careful not to oversell it, noting that the research is still early. In his closing remarks, Huberman returns to the episode's central argument: understanding the cortico-striatal-thalamic loop — why it misfires in OCD and how each treatment targets a different node — equips patients and their clinicians to make far better treatment decisions. He closes with empathy for those living with OCD, urging listeners who recognize themselves or someone they know to pursue informed, expert-guided care.
Claims made here
Myo-inositol at 900 milligrams or higher can improve sleep and may reduce anxiety.
Myo-inositol at 900 milligrams or higher appears to improve sleep and may reduce anxiety, making it a nutraceutical candidate worth exploring in OCD treatment.
No indexed bits in this chapter.
This episode
Columbia University MD/PhD and one of the world's foremost OCD researchers and clinicians, whose treatment protocols and studies are central to the episode's treatment section.
Smart mattress cover company and episode sponsor; their Pod 5 product is endorsed by Huberman for sleep temperature regulation.
U.S. government medical research agency that has launched a new Division of Complementary Health to formally study holistic treatments like meditation for psychiatric disorders.
Water filter company and episode sponsor; Huberman endorses their countertop filtration system for removing PFAS and other contaminants.
Institution where Dr. Helen Blair Simpson conducts her OCD research and clinical practice.
A newly launched NIH division dedicated to formally researching holistic and complementary treatments such as meditation and breathing practices for psychiatric conditions.
Andrew Huberman's academic home, where he is a professor of neurobiology and ophthalmology and teaches neuroanatomy.
Cited in sponsor segment for a 2020 study estimating over 200 million Americans are exposed to PFAS chemicals through tap water.
Non-invasive brain stimulation technology discussed as a promising but not yet definitive treatment for OCD, particularly when targeted at motor and supplementary motor areas.
The most widely used clinical assessment tool for OCD, spanning dozens of pages and categories, used to diagnose severity and identify the core fear driving a patient's symptoms.
Vitamin, mineral, and probiotic drink endorsed by Andrew Huberman as his daily foundational nutritional supplement; episode sponsor.
So-called 'forever chemicals' mentioned in the Rorra sponsor segment as contaminants in tap water linked to hormone disruption and other health issues.
Stats
This episode
Factual claims made this episode, and whether a source was named.
OCD affects 2.5% to 4% of the global population.
OCD is ranked number 7 among all illnesses worldwide in terms of debilitation, surpassing diseases like asthma and many cancers.
Approximately 40–50% of OCD cases have an identifiable genetic component, based on twin studies.
Dozens to hundreds of neuroimaging studies have identified the cortico-striatal-thalamic loop as the primary brain circuit generating OCD obsessions and compulsions.
SSRIs suppress activity in the cortico-striatal-thalamic loop, corresponding to their reduction of OCD symptoms.
Exposure-based CBT reduced OCD symptom severity scores (on a scale of 8–28) from approximately 25 down to about 11 within four weeks.
Combining SSRIs with CBT for OCD produced no additional reduction in symptoms compared to CBT alone.
There is very little, if any, evidence that the serotonin system is causally disrupted in OCD, despite SSRIs being partially effective.
Smoked cannabis (THC or CBD) had little acute impact on OCD symptoms and produced smaller anxiety reductions than placebo.
A 2020 study by the Environmental Working Group estimated that more than 200 million Americans are exposed to PFAS chemicals through drinking tap water.
TMS applied to motor and supplementary motor areas can reduce OCD compulsive behaviors even after the treatment session ends.
Myo-inositol at 900 milligrams or higher can improve sleep and may reduce anxiety.
Mindfulness meditation improves OCD symptoms indirectly by enhancing patients' engagement with CBT homework, rather than by directly relieving OCD symptoms.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.